ArticleBreast cancer research : BCR2026
Melanoma cell adhesion molecule (MCAM) mediates microtentacle generation, homotypic clustering, and reattachment of non-adherent breast tumor cells.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMelanoma cell adhesion molecule (MCAM) was first identified in advanced primary tumors and metastatic lesions. MCAM expression has been shown in previous studies to promote aggressive cancer phenotypes, including migration, invasion, tumorigenesis, and induction of vimentin and slug, indicative of EMT. Furthermore, overexpression of MCAM has been linked to poor prognosis and aggressive metastatic phenotypes, particularly in triple-negative breast cancer (TNBC). Early work has shown that MCAM can alter the actomyosin cytoskeleton and intermediate filaments; however, the impact of MCAM on the microtubule network and non-adherent cells has not been well studied.
methodsUtilizing MCF-10A breast epithelial cell line engineered to overexpress MCAM and CRISPR MCAM knockouts in TNBC cell lines, we assessed the impact of MCAM on tubulin-driven cytoskeletal phenotypes in non-adherent conditions. TetherChip technology, xCelligence RTCA, and immunoblotting techniques were utilized to investigate the impact of MCAM overexpression.
resultsOur results show that MCAM overexpression increases vimentin protein levels, α-tubulin post-translational modificaitons (PTMs), microtentacle (McTN) protrusions, homotypic cell clustering, cellular reattachment, and migration. These phenotypic increases can be inhibited with FDA-approved vinorelbine treatment. Conversely, the knockout of MCAM in TNBC cell lines sustains decreases of acetylated α-tubulin, implicating that MCAM expression may alter the microtubule cytoskeleton's stability directly. Knockout (KO) of MCAM also decreased microtentacle protrusions and McTN-supported phenotypes of homotypic cell clustering and cellular reattachment. Migration was also decreased in TNBC with MCAM KO.
conclusionsThese findings suggest that MCAM can function through the microtubules in TNBC to impact McTN-supported phenotypes of homotypic cell clustering and cellular reattachment in non-adherent breast tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.